title: Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats.
abstract: To investigate the therapeutic effect of different doses of low energy shock wave therapy (LESWT) on the erectile dysfunction (ED) in streptozotocin (STZ) induced diabetic rats. SD rats (n = 75) were randomly divided into 5 groups (normal control, diabetic control, 3 different dose LESWT treated diabetic groups). Diabetic rats were induced by intra-peritoneal injection of STZ (60 mg/kg) and rats with fasting blood glucose ≥ 300 mg/dL were selected as diabetic models. Twelve weeks later, different doses of LESWT (100, 200 and 300 shocks each time) treatment on penises were used to treat ED (7.33 MPa, 2 shocks/s) three times a week for two weeks. The erectile function was evaluated by intracavernous pressure (ICP) after 1 week washout period. Then the penises were harvested for histological study. The results showed LESWT could significantly improve the erectile function of diabetic rats, increase smooth muscle and endothelial contents, up-regulate the expression of α-SMA, vWF, nNOS and VEGF, and down- regulate the expression of RAGE in corpus cavernosum. The therapeutic effect might relate to treatment dose positively, and the maximal therapeutic effect was noted in the LESWT300 group. Consequently, 300 shocks each time might be the ideal LESWT dose for diabetic ED treatment.
authors.affiliation: Andrology Center, Peking University First Hospital, Peking University, Beijing 100034, China. xinzc@bjmu.edu.cn.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Feng
authors.initials: F
authors.lastname: Zhou
authors.forename: Guang-Yong
authors.initials: GY
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Hui-Xi
authors.initials: HX
authors.lastname: Li
authors.forename: Guang-Yi
authors.initials: GY
authors.lastname: Bai
authors.forename: Rui-Li
authors.initials: RL
authors.lastname: Guan
authors.forename: Yong-De
authors.initials: YD
authors.lastname: Xu
authors.forename: Ze-Zhu
authors.initials: ZZ
authors.lastname: Gao
authors.forename: Wen-Jie
authors.initials: WJ
authors.lastname: Tian
authors.forename: Zhong-Cheng
authors.initials: ZC
authors.lastname: Xin
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D015153:Blotting, Western; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004727:Endothelium / Q000378:metabolism; D007172:Erectile Dysfunction / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy*; D007150:Immunohistochemistry; D008297:Male; D008856:Microscopy, Fluorescence; D009130:Muscle, Smooth / Q000378:metabolism; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism; D010413:Penis / Q000378:metabolism / Q000503:physiopathology; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism; D016896:Treatment Outcome; D014464:Ultrasonic Therapy / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D000199:Actins; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D042461:Vascular Endothelial Growth Factor A; D014841:von Willebrand Factor; D052248:Nitric Oxide Synthase Type I